Takip et
A/Prof Michael Dickinson, Haematologist
A/Prof Michael Dickinson, Haematologist
Peter MacCallum Cancer Centre, Melbourne Australia
petermac.org üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma
FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, ...
New England Journal of Medicine 386 (7), 640-654, 2022
7442022
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia
DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai, K Tainton, K Chen, ...
Molecular Therapy 21 (11), 2122-2129, 2013
4842013
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
F Morschhauser, H Tilly, A Chaidos, P McKay, T Phillips, S Assouline, ...
The Lancet Oncology 21 (11), 1433-1442, 2020
3832020
Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma
MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ...
New England Journal of Medicine 386 (7), 629-639, 2022
3152022
Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial
M Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, ...
Journal of Clinical Oncology 39 (18), 1959, 2021
2872021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ...
Nature medicine 28 (2), 325-332, 2022
2552022
Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy
CFM Hughes, A Khot, C McCormack, S Lade, DA Westerman, R Twigger, ...
Blood, The Journal of the American Society of Hematology 125 (1), 71-81, 2015
2202015
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma
MJ Dickinson, C Carlo-Stella, F Morschhauser, E Bachy, P Corradini, ...
New England Journal of Medicine 387 (24), 2220-2231, 2022
1932022
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
M Dickinson, RW Johnstone, HM Prince
Investigational new drugs 28, 3-20, 2010
1692010
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase …
J Kuruvilla, R Ramchandren, A Santoro, E Paszkiewicz-Kozik, ...
The Lancet Oncology 22 (4), 512-524, 2021
1642021
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
SS Neelapu, M Dickinson, J Munoz, ML Ulrickson, C Thieblemont, ...
Nature medicine 28 (4), 735-742, 2022
1632022
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma
CY Cheah, KE Herbert, K O'rourke, GA Kennedy, A George, PL Fedele, ...
British journal of cancer 111 (6), 1072-1079, 2014
1522014
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma
M Dickinson, D Ritchie, DJ DeAngelo, A Spencer, OG Ottmann, T Fischer, ...
British journal of haematology 147 (1), 97-101, 2009
1142009
Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre‐transplant FDG‐PET scan following salvage chemotherapy
M Dickinson, R Hoyt, AW Roberts, A Grigg, JF Seymour, HM Prince, ...
British journal of haematology 150 (1), 39-45, 2010
1002010
Romidepsin for cutaneous T-cell lymphoma
HM Prince, M Dickinson
Clinical Cancer Research 18 (13), 3509-3515, 2012
992012
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
SJ Harrison, H Quach, E Link, JF Seymour, DS Ritchie, S Ruell, J Dean, ...
Blood, The Journal of the American Society of Hematology 118 (24), 6274-6283, 2011
932011
Survival with axicabtagene ciloleucel in large B-cell lymphoma
JR Westin, OO Oluwole, MJ Kersten, DB Miklos, MA Perales, A Ghobadi, ...
New England Journal of Medicine 389 (2), 148-157, 2023
912023
Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts
B Reis, L Jukofsky, G Chen, G Martinelli, H Zhong, WV So, MJ Dickinson, ...
Haematologica 101 (5), e185, 2016
872016
Azacitidine with or without eltrombopag for first-line treatment of intermediate-or high-risk MDS with thrombocytopenia
M Dickinson, H Cherif, P Fenaux, M Mittelman, A Verma, MSO Portella, ...
Blood, The Journal of the American Society of Hematology 132 (25), 2629-2638, 2018
862018
Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin Lymphomas
F Morschhauser, G Salles, P McKay, H Tilly, A Schmitt, J Gerecitano, ...
Hematological Oncology 35, 24-25, 2017
822017
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20